儿童适配风险指数预测儿童造血干细胞移植后2年移植相关死亡率
在单中心874例儿童944次造血干细胞移植中重新验证HCT-CI,发现其不适用后提出儿童适配风险指数(PARI),按风险因素与合并症赋权分组,2年移植相关死亡率从1组6.2%线性升至4组50.9%,内部与外部队列验证成功。
要点
- HCT-CI在该儿童队列中不适用,故提出儿童适配风险指数PARI。
- PARI按风险因素与合并症赋权0–3分,分4组,2年移植相关死亡率1组6.2%至4组50.9%线性上升。
- PARI在内部与外部儿童队列验证成功,预测2年移植相关死亡率优于HCT-CI。
核心结论
- PARI在预测儿童2年移植相关死亡率方面优于HCT-CI,作者认为其有助于为造血干细胞移植儿童提供更好的咨询与决策。
研究设计与样本
- 单中心874例儿童共944次造血干细胞移植(恶性或非恶性疾病)的HCT-CI重新验证研究。
- 在发现HCT-CI不适用后,提出纳入儿科相关风险因素与合并症的改良评分系统PARI。
- 按风险因素/合并症对移植相关死亡率的风险比赋整数权重:0(HR<1.2)、1(1.2≥HR<1.75)、2(1.75≥HR<2.5)、3(HR≥2.5)。
- 按PARI评分分4组:1组无风险因素/合并症;2组评分1–2;3组评分3–4;4组评分≥5。
- PARI在内部和外部儿童患者队列中验证。
主要发现
- 2年移植相关死亡率从1组至4组线性上升:1组6.2%,4组50.9%。
- PARI预测儿童2年移植相关死亡率的c统计量表现优于HCT-CI。
- 使用PARI时Akaike信息准则为1069.245、Schwarz贝叶斯信息准则为1073.269。
- 使用HCT-CI时Akaike信息准则为1223.158、Schwarz贝叶斯信息准则为1227.051。
关键数值与推荐
- 风险因素/合并症权重赋值:HR<1.2为0分;1.2≥HR<1.75为1分;1.75≥HR<2.5为2分;HR≥2.5为3分。
- 风险分组:1组无风险因素/合并症;2组评分1–2;3组评分3–4;4组评分≥5。
临床怎么用
- 作者认为PARI将成为有价值的工具,有助于为造血干细胞移植儿童提供更好的咨询与决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several attempts have been made to optimize pretransplant risk assessment to improve hematopoietic stem cell transplantation (HSCT) decision-making and to predict post-HSCT outcomes. However, the relevance of pretransplant risk assessment to the pediatric population remains unclear. We report the results of revalidation of the hematopoietic cell transplantation comorbidity index (HCT-CI) in 874 children who received 944 HSCTs for malignant or nonmalignant diseases at a single center. After finding the HCT-CI invalid in our patient population, we proposed a modified pediatric adapted scoring system that captures risk factors (RFs) and comorbidities (CoMs) relevant to pediatrics. Each RF/CoM was assigned an integer weight based on its hazard ratio (HR) for transplant-related mortality (TRM): 0 (HR < 1.2), 1 (1.2 ≥ HR < 1.75), 2 (1.75 ≥ HR < 2.5), and 3 (HR ≥ 2.5). Using these weights, the pediatric adapted risk index (PARI) for HSCT was devised, and patients were divided into 4 risk groups (group 1: without RF/CoM; group 2: score 1-2; group 3: score 3-4; and group 4: score ≥5). There was a linear increase in 2-year TRM from group 1 to 4 (TRM, 6.2% in group 1, 50.9% in group 4). PARI was successfully validated on an internal and external cohort of pediatric patients. Comparing models using c-statistics, PARI was found to have better performance than HCT-CI in predicting 2-year TRM in children, with Akaike and Schwarz Bayesian information criteria values of 1069.245 and 1073.269, respectively, using PARI, vs 1223.158 and 1227.051, respectively, using HCT-CI. We believe that PARI will be a valuable tool enabling better counseling and decision-making for pediatric patients with HSCT.
引用
- Elfeky R, Builes N, Pearce R, et al. Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children. Blood Adv. 2024. PMID: 39093984. doi:10.1182/bloodadvances.2024013484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。